Longest ever follow-up study of a targeted cancer therapy shows excellent results

ATLANTA, Ga. - The overall survival of most people with chronic myelogenous leukemia (CML) treated with imatinib (Gleevec, STI-571) is extremely high and the relapse rate is quite low, according to new data from a study out of the Oregon Health & Science University Cancer Institute. The overall survival at five years is 89 percent as compared to no more than 50 percent with prior therapies, and the risk of relapse continues to decrease the longer patients take the drug.

"This represents a complete turn around in the prognosis for patients with this disease," said Brian J. Druker, M.D., who originally collaborated with Novartis scientists to develop Gleevec into a successful treatment for CML. He is the JELD-WEN chair of leukemia research in the OHSU Cancer Institute and an investigator of the Howard Hughes Medical Institute.

Druker presented the five-year update from the IRIS (International Randomized IFN vs. ST1571) Study Group on Saturday, June 3 at the 2006 annual meeting of the American Society of Clinical Oncology in Atlanta, Ga.

Begun in June 2000, the phase III trial involved 1,106 subjects at 117 centers in 16 countries. Subjects were in CML's chronic phase, the most common stage of the disease, and had not previously received chemotherapy. Half were randomized to receive Gleevec and half to receive the standard treatment at the time the trial started, interferon-alpha and cytarabine arabinoside. Participants in the interferon arm were later allowed to cross over to Gleevec. Just 3 percent remain on interferon therapy.

"Prior to this, we had to project what the five-year survival data would be and worried that the risk of relapse might increase. With this data, we have increased confidence in this targeted therapy," Druker said.

At five years, the overall survival of the 553 subjects randomized to receive Gleevec as their initial therapy was 89 percent; 95 percent if only deaths related to CML are con

Contact: Rachel MacKnight
Oregon Health & Science University

Page: 1 2

Related medicine news :

1. Regular follow-up important during antidepressant treatment
2. UCLA/VA study: Many patients not receiving follow-up tests after positive screening for colon cancer
3. Short term follow-up proves to be helpful
4. St. Jude develops more affordable ALL follow-up test
5. Physician counseling, at-home follow-up may improve teen health behaviors
6. Accentia Biopharmaceuticals announces that follow-up data
7. Tamoxifen reduces risk of breast cancer, follow-up study confirms
8. Single-visit program for cervical cancer screening increases rate of follow-up, treatment
9. Preliminary data update from Betaseron 16 yr. long-term follow-up study in patients with MS
10. Insurance status affects ability to secure necessary, timely follow-up medical appointments
11. Children with high blood lead levels often do not receive follow-up tests

Post Your Comments:

(Date:10/13/2017)... ... 2017 , ... The International Association of Eating Disorders Professionals ... the field of eating disorders, announces the opening of early registration for the ... at the Omni Resort at ChampionsGate. , The annual iaedp™ Symposium ...
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated stainless ... FDA requirements, which stipulates new criteria regarding medical device manufacture and ... ID jewelry such as Medical ID Bracelets, can rest assured that ... the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process with ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance in ... medical-grade battery-powered display stand specifically designed for endoscopy environments. An innovative ... into a clinical solution to support the improvement of patient outcomes, ... Design ... Solution ...
Breaking Medicine Technology:
Cached News: